GO
Loading...

Pfizer Inc

More

  • Pfizer Finding Innovation At Medivation Wednesday, 3 Sep 2008 | 10:32 AM ET
    Lilly Effient

    In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).

  • For Widely Used Drug, Question of Usefulness Lingers Tuesday, 2 Sep 2008 | 4:51 AM ET

    When the Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that it had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug, the New Yor Times reported.

  • Financials Lead Stocks to a Higher Finish Wednesday, 27 Aug 2008 | 5:21 PM ET

    Stocks finished higher in feather-light trading Wednesday, boosted by a rise in financials and energy stocks, as well as a better-than-expected durable-goods report.

  • When It Rains Risk, It Pours Wednesday, 27 Aug 2008 | 12:01 PM ET

    Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals and Cell Genesys, much lower. After the closing bell Tuesday, Bristol-Myers Squibb and Pfizer had an announcement to make...

  • Pfizer Vs. Johnson & Johnson Tuesday, 26 Aug 2008 | 6:28 PM ET

    Cramer shows you how to value each stock so you know which is the better pick.

  • Stanford to Limit Drug Maker Financing Tuesday, 26 Aug 2008 | 11:09 AM ET
    Green wedding

    Stanford University, concerned about the influence drug companies may have on medical education, is expected to announce Tuesday that it will severely restrict industry financing of doctors’ continuing education at its medical school, according to the New York Times.

  • AstraZeneca's Flu Campaign Season Begins Monday, 25 Aug 2008 | 12:35 PM ET
    Flu Vaccination Button

    Talk about timely direct-to-consumer advertising. Last week ,I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political.

  • Of Football, Pfizer and Pharma Friday, 22 Aug 2008 | 11:31 AM ET

    As we head into my last free summer weekend before USC's football season kicks off, I wanted to clean out the Pharma's Market mailbox. (Actually I was looking for an apropos-of-nothing excuse to mention the Trojans.)

  • Highest Yielding Stocks On The S&P Wednesday, 20 Aug 2008 | 9:02 AM ET

    Earlier this week, we wrote about the highest yielding stocks on the Dow.  The S&P 500 also has some nice yielding stocks.  If you are worried about the financials being able to continue to pay thier big dividends (with Freddie Mac's big slide, its yield is now over 20%!), there are nearly 40 stocks on the S&P that are currently yielding 5% or more.  Here's a breakdown.

  • Best Trades Now: Healthcare, Growth Stocks & More Monday, 18 Aug 2008 | 1:42 PM ET

    To give investors an edge, CNBC asked the experts for their best trades now.

  • Highest Yielding Stocks On The Dow Monday, 18 Aug 2008 | 9:30 AM ET
    A Bank of America branch.

    Do you believe that financials, pharma and telecom can maintain through an economic downturn? If so, you might want to take a look at the Dow Industrials where some of the largest companies in the world are currently offering investors notably large dividend yields.

  • Abbott's Covering The Bases Thursday, 14 Aug 2008 | 1:28 PM ET

    The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.

  • Are Big Pharma's Dollar Days Almost Over? Tuesday, 12 Aug 2008 | 3:18 PM ET
    Pharma Stocks

    For quite some time now the major American pharmaceutical companies have been benefitting from the foreign exchange rate. But given the recent strength in the greenback, Deutsche Bank analyst Barbara Ryan says the sector may not be able to rely on forex for very much longer.

  • Pfizer Breaks A Barrier Monday, 11 Aug 2008 | 3:26 PM ET

    I wanted to be sure and call attention to the fact that PFE is no longer a teenager. Shares of the Dow component have broken above $20. If the stock can stay there at 4 p.m. that'll be the first time Pfizer's closed above that level since May 21st.

  • Best Trades Now: Healthcare, Tech & More Monday, 11 Aug 2008 | 2:31 PM ET

    To give investors an edge, CNBC asked the experts for their best trades now.

  • Stock Picks: Come Back to the USA Monday, 11 Aug 2008 | 10:04 AM ET

    After Wall Street's best week in a long time, Bob Doll, BlackRock vice chairman and CIO of global equities, calls the U.S. "the best house in a bad neighborhood."

  • Recession-Fighter Stocks (Part 2) Friday, 8 Aug 2008 | 1:13 PM ET

    David Pearl of Epoch Investment Partners and David Moon of Moon Capital Management offered CNBC their insights. (Part 2: Personal Products)

  • Elan On Eight-Eight-Oh-Eight, Etc. Friday, 8 Aug 2008 | 11:47 AM ET
    Elan

    The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.

  • Dorfman's Rx for Your Portfolio Wednesday, 6 Aug 2008 | 10:21 AM ET

    John Dorfman's prescription for a portfolio: A pharmaceutical, a defense contractor, a media company, and a technology stock.

  • Stocks Finish Lower, Despite Oil Plunge Monday, 4 Aug 2008 | 4:11 PM ET

    Stocks finished lower Monday, as weakness in financials and energy stocks overpowered a sharp drop in oil price typical of what usually pushes the market higher.